ResearchMoz

Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs

GBI Research
Published Date » 2014-06-02
No. Of Pages » N/A
   
 GBI Research, the leading business intelligence provider, has released its latest research: ‘Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs ’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the eight major markets – The US, The...
Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Introduction 9
2.1 Breast Cancer 9
2.2 Symptoms 9
2.3 Epidemiology 10
2.4 Pathophysiology 11
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 12
2.6.1 Classification 13
2.7 Treatment Options 14
2.7.1 Surgery and Radiation Therapy 14
2.7.2 Chemotherapy 14
2.7.3 Hormonal Therapies 15
2.7.4 Targeted Therapies 15
2.7.5 Resistance to Pharmacological Therapies 16
2.7.6 Treatment Guidelines 17
2.7.7 Measuring the Effectiveness of Treatment 18

3 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Marketed Products 20
3.1 Key Marketed Products 20
3.1.1 Herceptin 20
3.1.2 Halaven 21
3.1.3 Avastin 22
3.1.4 Gemzar 23
3.1.5 Taxotere 23
3.1.6 Tykerb 24
3.1.7 Femara 25
3.1.8 Aromasin 26
3.1.9 Zoladex 26
3.1.10 Arimidex 27
3.2 Heat Map for Marketed Products 27

4 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Pipeline Analysis 29
4.1 Overall Pipeline 29
4.2 Pipeline Analysis by Molecule Type 31
4.3 Pipeline Analysis by Mechanism of Action 33
4.4 Clinical Trials - Failure Rate 35
4.5 Clinical Trial Size 37
4.6 Duration 39
4.7 Promising Drug Candidates in Pipeline 40
4.7.1 Buparlisib 40
4.7.2 Palbociclib 40
4.7.3 Afatinib dimaleate 40
4.7.4 Entinostat 41
4.7.5 Neratinib 42
4.7.6 BMN-673 42
4.7.7 Etirinotecan pegol 42
4.7.8 MetmAb (onartuzumab) 43

5 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Market Forecast to 2020 44
5.1 Global Market 44
5.1.1 Treatment Use Patterns 44
5.1.2 Market Size 44
5.2 North America 46
5.2.1 Treatment Use Patterns 46
5.2.2 Annual Cost of Therapy 47
5.2.3 Market Size 49
5.3 Top Five European Markets 51
5.3.1 Treatment Use Patterns 51
5.3.2 Annual Cost of Therapy 52
5.3.3 Market Size 53
5.4 Japan 54
5.4.1 Treatment Use Patterns 54
5.4.2 Annual Cost of Therapy 54
5.4.3 Market Size 54
5.5 Drivers and Barriers for the Breast Cancer Therapeutics in Asia-Pacific Market to 2020 56
5.5.1 Drivers 56
5.5.2 Barriers 56

6 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Deals and Strategic Consolidations 58
6.1 Licensing Agreements 58
6.1.1 Major Licensing Deals 61
6.2 Co-development Agreements 62
6.2.1 Major Co-development Agreements 64

7 Breast Cancer Therapeutics in Major Developed Markets to 2020 – Appendix 66
7.1 All Pipeline Drugs by Phase 66
7.1.1 Discovery 66
7.1.2 Preclinical 69
7.1.3 IND/CTA-Filed and Phase I 79
7.1.4 Phase II 85
7.1.5 Phase III 91
7.1.6 Pre-Registration 93
7.2 Market Forecasts to 2020 94
7.2.1 Global 94
7.2.2 US 94
7.2.3 Canada 95
7.2.4 UK 95
7.2.5 France 95
7.2.6 Germany 96
7.2.7 Italy 96
7.2.8 Spain 96
7.2.9 Japan 97
7.3 Market Definitions 97
7.4 Abbreviations 97
7.5 References 99
7.6 Research Methodology 102
7.6.1 Coverage 102
7.6.2 Secondary Research 102
7.6.3 Primary Research 103
7.6.4 Therapeutic Landscape 103
7.6.5 Geographical Landscape 105
7.6.6 Pipeline Analysis 106
7.7 Expert Panel Validation 106
7.8 Contact Us 106
7.9 Disclaimer 106

List of Tables

Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010–2013 12
Table 2: Breast Cancer Therapeutics, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013 13
Table 3: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 66
Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013 69
Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed and Phase I), 2013 79
Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 85
Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013 91
Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Pre-Registration), 2013 93
Table 9: Breast Cancer Therapeutics, Global, Forecast Data, 2013–2020 94
Table 10: Breast Cancer Therapeutics, US, Forecast Data, 2013–2020 94
Table 11: Breast Cancer Therapeutics, Canada, Forecast Data, 2013–2020 95
Table 12: Breast Cancer Therapeutics, UK, Forecast Data, 2013–2020 95
Table 13: Breast Cancer Therapeutics, France, Forecast Data, 2013–2020 95
Table 14: Breast Cancer Therapeutics, Germany, Forecast Data, 2013–2020 96
Table 15: Breast Cancer Therapeutics, Italy, Forecast Data, 2013–2020 96
Table 16: Breast Cancer Therapeutics, Spain, Forecast Data, 2013–2020 96
Table 17: Breast Cancer Therapeutics, Japan, Forecast Data, 2013–2020 97

List of Figures

Figure 1: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2013 17
Figure 2: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2013 18
Figure 3: Breast Cancer Therapeutics, Global, Heat Map (Marketed Products) 28
Figure 4: Breast Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2013 30
Figure 5: Breast Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2013 32
Figure 6: Breast Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2013 34
Figure 7: Breast Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2013 36
Figure 8: Breast Cancer Therapeutics, Global, Clinical Trial Size, 2013 38
Figure 9: Breast Cancer Therapeutics, Global, Clinical Trial Duration (months), 2013 39
Figure 10: Breast Cancer Therapeutics, Global, Treatment Use Patterns (‘000) and Market Size ($bn), 2013–2020 45
Figure 11: Breast Cancer Therapeutics, US and Canada, Treatment Use Patterns (‘000), 2013–2020 46
Figure 12: Breast Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2013–2020 48
Figure 13: Breast Cancer Therapeutics, US and Canada, Market Size ($m), 2013–2020 50
Figure 14: Breast Cancer Therapeutics, Top Five European Markets, Treatment Use Patterns (‘000), 2013–2020 51
Figure 15: Breast Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2013–2020 52
Figure 16: Breast Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2013–2020 53
Figure 17: Breast Cancer Therapeutics, Japan, Treatment Use Pattern, Annual Cost of Therapy and Market Size, 2013–2020 55
Figure 18: Breast Cancer Therapeutics, Global, Licensing Deals by Phase and Value, 2006–2013 58
Figure 19: Breast Cancer Therapeutics, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2013 59
Figure 20: Breast Cancer Therapeutics, Global, Licensing Deals by Region, 2006–2013 60
Figure 21: Breast Cancer Therapeutics, Global, Co-development Deals by Phase and Value, 2006–2013 62
Figure 22: Breast Cancer Therapeutics, Global, Co-development Deals, 2006–2013 63
Figure 23: GBI Research Market Forecasting Model 105

Upcoming Reports:

Greece: market of fresh and chilled chicken meat
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the fresh and chilled chicken meat market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the fresh and chilled chicken meat market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Laboratory Plasticware Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Laboratory plasticware are equipment made up of polymers having variety of applications with respect to laboratory or research centers. The laboratory plasticware market has significantly evolved itself in past few decades in terms of material composition, design and application. Laboratory plasticware encompasses number of advantages such as being unbreakable in nature enhances its applicability with respect to handling radioactive isotopes, hazardous and carcinogenic chemicals or substances. The inherent characteristics of the equipment include environmental friendliness,...
EEG/EMG Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2013 - 2019
By - Transparency Market Research
Electroencephalography (EEG) and Electromyography (EMG) equipment is used to monitor electrical activity on the body. EEG measures the fluctuation in voltage resulting from the current flow of the brain while, EMG records the electrical activity of skeletal muscles. In EEG and EMG, electric signals are read for brain and muscle tissue respectively, can are amplified and digitized which can be later analyzed and processed on a computer. This has helped in understanding brain-muscle coordination and also assisted in neural therapies. EEG is most often used to diagnose epilepsy,...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Recalls 65,000 Fusion Models Due to Issues in Ignition Key
Nov 20, 2014  
If anything defines the world of automobiles currently, it would be recalls. It seems that a flood of automobiles has surrounded the global automobiles industry, which once represented a flourishing and highly profitable industry.  The current automobile giants ordering yet another recall is Ford Motors Co. Ford declared on Tuesday that it is recalling nearly 65,000 sedans from...
3D Printed Heart Model for Better Cardiological Treatment
Nov 20, 2014  
According to research carried out by the American Heart Association’s Scientific Sessions 2014, surgeons will be able to treat complex heart disorders in patients, with the help of a three dimensional experimental printed model of the heart. For surgical planning, most cardiac surgeons make use of two dimensional images of the heart taken by MRI, ultrasound, and X-ray. But the problem is...
Los Angeles Auto Show Kicks Off
Nov 20, 2014  
The Los Angeles Auto Show kicked off on Wednesday with a rather upbeat mood. Motoring machines, industry metrics, and hybrid models – the show has lived up to its reputation once more. The Los Angeles Auto Show has begun touring North America from the Los Angeles Convention Center, and the commencement has already had an impact on the market. Gasoline prices dropped under US$3...
Scottish Government to Inject 200 Million Pounds in the Housing Sector
Nov 19, 2014  
The construction and the housing industries of Scotland will get a major financial boost from the Scottish government in terms of additional funding worth 200 million pounds. The main rationale of such a financial boost is to stimulate the housing sector and also safeguarding employment in the construction industry. The housing minister of Scotland has requested the housing leaders to work...
Quarterly Dividend of $0.10 Declared by Tyson Foods, Inc.
Nov 19, 2014  
A quarterly dividend on November 18th was declared by Tyson Foods, reported Analyst Ratings Network.com. The shareholders of the February 27th record will be awarded a dividend of 0.10 per share on March 13th.  This represents a yield of 0.94% and a $0.40 dividend on an annualized basis. However, the ex-dividend date of this particular dividend is February 25th.  Such...